Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc is a pioneering force in the field of oncology, focusing on the development of radiopharmaceuticals as targeted cancer treatments. With operations in Canada and the United States, the company's innovative approach is exemplified by its leading product candidates, including FPI-2265 for prostate cancer and FPI-1434 for various solid tumors. Beyond its clinical trials, Fusion Pharmaceuticals is exploring potential cancer therapies in collaboration with AstraZeneca, aiming to revolutionize cancer treatment through precision medicine. Founded in 2014 and based in Hamilton, Canada, Fusion is at the forefront of combating cancer with cutting-edge science.